Immix Biopharma (IMMX) Change in Cash (2021 - 2026)

Immix Biopharma (IMMX) has 6 years of Change in Cash data on file, last reported at -$14.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 733.6% year-over-year to -$14.7 million; the trailing twelve-month figure through Mar 2026 stood at $63.3 million (up 572.67% YoY), and the FY2025 full-year result was $76.2 million, up 44187.46% from the prior year.
• Change in Cash slipped to -$14.7 million in Q1 2026, from $78.0 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $78.0 million in Q4 2025 to a low of -$14.7 million in Q1 2026.
• A 5-year average of $3.6 million and a median of -$1.8 million in 2025 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash slumped 1946.43% in 2022 and jumped 3982.61% in 2025, its largest moves.
• Tracing IMMX's Change in Cash over 5 years: stood at -$3.5 million in 2022, then surged by 40.44% to -$2.1 million in 2023, then gained by 3.1% to -$2.0 million in 2024, then jumped by 3982.61% to $78.0 million in 2025, then tumbled by 118.82% to -$14.7 million in 2026.
• Business Quant data shows IMMX's Change in Cash at -$14.7 million in Q1 2026, $78.0 million in Q4 2025, and $4.3 million in Q3 2025.